Steps Forward in the MyNewGut Project
The MyNewGut project's recent progress and expected outcomes for 2016 were revealed by the Project Coordinator, Professor Yolanda Sanz of the Spanish National Research Council (CSIC), in an interview with 'Gut Microbiota for Health'. See what Yolanda had to say.
MyNewGut workshop lays out plans for re-figuring fibre recommendations
MyNewGut Project Coordinator, Professor Yolanda Sanz of the Spanish National Research Council (CSIC), recently spoke with 'Gut Microbiota for Health' about MyNewGut's fibre studies.
Why is it important to study fibre and how it affects the gut microbiota?
Ideally, how will this MyNewGut data inform new food-based public health recommendations?
See what Yolanda had to say.
The MyNewGut consortium came together 15-17 April, in Bologna, for the first annual meeting. Partners shared and discussed the developments and upcoming activities of the project. We were joined by two members of the MyNewGut Scientific Advisory Board, Dr Garrath Williams of the University of Lancaster and Dr Anthony Leeds a Senior Visiting Fellow of the University of Surrey. The Scientific Advisory Board engages international scientific leaders in the study of host-microbe interactions, diet, nutrition, lifestyle, health and diet related diseases with the aim to advise on scientific and ethical issues.
For example, there is growing evidence to suggest that autism spectrum and eating disorders, cardiovascular disease and metabolic conditions such as obesity and type 2 diabetes may all be associated with microbial imbalances in the gut, explains Sandrine Claus, a lecturer in metabolomics at the University of Reading, UK.
"The microbiome field has produced some of the most exciting science discoveries of the last five years, and its potential impact on human health is just too big to ignore"
If confirmed, these findings could have an enormous impact on human health. The benefits for treating diabetes alone, which affects over 300 million people globally, could be transformational. “If we were able to prevent the disease’s complications by manipulating the gut microbiome in only 10 per cent of patients, this would still equate to millions of people with a preserved quality of life", says Dr Claus.
The Economist also published a short video MyNewGut project's Dr Sandrine Claus, of the University of Reading, explains what microbial medicine means, some of its most promising applications, and why bacteria might one day replace pills as the main way to deliver medicine. Click here to watch the video.